Table 2.
Correlation between PD-L1 antibody, clone QR and the clinicopathological features
| PD-L1 IHC clone QR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | TPS | IC | |||||||
| Feature | Positive (n/%) | Negative (n/%) | p value | Positive (n/%) | Negative (n/%) | p value | Positive (n/%) | Negative (n/%) | p value |
|
Gender Male Female |
66 (41.3) 97 (52.4) |
94 (58.8) 88 (47.6) |
0.025 |
21 (13.0) 40 (21.5) |
140 (87.0) 146 (78.5) |
0.027 |
63 (39.1) 94 (50.5) |
98 (60.9) 92 (49.5) |
0.022 |
|
pT 1 2 3 4 |
9 (40.9) 20 (41.3) 104 (50.7) 30 (38.0) |
13 (59.1) 19 (48.7) 101 (49.3) 49 (62.0) |
0.228 |
3 (13.0) 5 (12.8) 40 (19.4) 13 (16.5) |
20 (87.0) 34 (87.2) 166 (80.6) 66 (83.5) |
0.686 |
9 (39.1) 20 (51.3) 99 (48.1) 29 (36.7) |
14 (60.9) 19 (48.7) 107 (51.9) 50 (63.3) |
0.272 |
|
pN 0 1 2 |
108 (54.5) 42 (47.5) 17 (25.4) |
90 (45.5) 38 (52.5) 50 (74.6) |
< 0.001 |
36 (18.2) 19 (23.2) 6 (9.0) |
162 (81.8) 63 (76.8) 61 (91.0) |
0.072 |
105 (53.0) 36 (43.9) 16 (23.9) |
93 (47.0) 46 (56.1) 51 (76.1) |
< 0.001 |
|
M 0 1 |
154 (53.1) 9 (16.4) |
136 (46.9) 46 (83.6) |
< 0.001 |
56 (19.2) 5 (9.1) |
236 (80.8) 50 (90.9) |
0.047 |
149 (51.0) 8 (14.5) |
143 (49.0) 47 (85.5) |
< 0.001 |
|
Grading Low grade High grade |
121 (44.0) 42 (60.0) |
154 (56.0) 28 (40.0) |
0.012 |
39 (14.1) 22 (31.4) |
238 (95.9) 48 (68.6) |
0.001 |
117 (42.2) 40 (57.1) |
160 (57.8) 30 (42.9) |
0.018 |
|
Mucinous Yes No (NOS) |
7 (29.2) 156 (58.6) |
17 (70.8) 165 (51.4) |
0.050 |
0 (0.0) 61 (18.9) |
24 (100.0) 262 (81.1) |
0.008 |
7 (29.2) 150 (46.4) |
17 (70.8) 173 (53.6) |
0.075 |
|
TNM stage I II III IV |
25 (49.0) 83 (59.3) 45 (47.4) 10 (16.9) |
26 (51.0) 57 (40.7) 50 (52.6) 49 (83.1) |
< 0.001 |
7 (13.7) 30 (21.4) 19 (19.6) 5 (8.5) |
44 (86.3) 110 (78.6) 78 (80.4) 54 (91.5) |
0.133 |
25 (49.0) 80 (57.1) 43 (44.3) 9 (15.3) |
26 (51.0) 60 (42.9) 54 (55.7) 50 (84.7) |
< 0.001 |
|
Localization Right-sided Left-sided |
126 (53.4) 37 (33.9) |
110 (46.6) 72 (66.1) |
0.001 |
47 (19.7) 14 (12.8) |
191 (80.3) 95 (87.2) |
0.076 |
121 (50.8) 36 (33.0) |
117 (49.2) 73 (67.0) |
0.001 |
|
L 0 1 |
106 (50.7) 57 (41.99 |
103 (41.9) 79 (58.1) |
0.068 |
35 (16.6) 26 (19.1) |
176 (83.4) 110 (80.9) |
0.321 |
104 (49.3) 53 (39.0) |
107 (50.7) 83 (61.0) |
0.038 |
|
V 0 1 |
138 (50.7) 25 (34.2) |
134 (49.3) 48 (65.8) |
0.008 |
49 (17.9) 12 (16.4) |
225 (82.1) 61 (83.6) |
0.463 |
132 (48.2) 25 (34.2) |
142 (51.8) 48 (65.8) |
0.023 |
|
KRAS Wild type Mutated |
19 (39.6) 16 (36.4) |
29 (60.4) 28 (63.6) |
0.459 |
5 (10.2) 4 (9.1) |
44 (89.8) 40 (90.9) |
0.569 |
19 (38.8) 15 (34.1) |
30 (61.2) 29 (65.9) |
0.401 |
|
MMR Proficient Deficient |
101 (42.4) 48 (65.8) |
137 (57.6) 25 (34.2) |
< 0.001 |
31 (13.0) 23 (31.5) |
208 (87.0) 50 (68.5) |
< 0.001 |
97 (40.6) 47 (64.4) |
142 (59.4) 26 (35.6) |
< 0.001 |
|
Budding Low Intermediate High |
130 (49.2) 30 (43.5) 3 (25.0) |
134 (50.8) 39 (56.5) 9 (75.0) |
0.098 |
52 (19.5) 9 (87.0) 0 (0.0) |
214 (80.5) 60 (13.0) 12 (100.0) |
0.044 |
126 (47.4) 28 (40.6) 3 (25.0) |
140 (52.6) 41 (59.4) 9 (75.0) |
0.091 |
|
TILs ≤ 5% > 5% |
63 (35.8) 100 (59.2) |
113 (64.2) 69 (40.8) |
< 0.001 |
15 (8.5) 46 (27.1) |
162 (91.5) 124 (72.9) |
< 0.001 |
60 (33.9) 97 (57.1) |
117 (66.1) 73 (42.9) |
< 0.001 |
Statistically significant values are indicated in italics
IHC immunohistochemistry, TPS tumor positivity score, IC immunocell score, TILs tumor-infiltrating lymphocytes, TNM tumor node metastasis, KRAS Kirsten rat sarkoma, MMR mismatch repair